9406-074 
9406-075 
9406-076 
9406-077 
9406-078 
9406-079 
9406-080 
9406-081 
9408-082 
AttadTrnt II - Ree 11 
(T/O/Rheumatoid Arthritis) 
Evans. C. H. and Robbins. Paul: University of Pittsbureh. Pittsburgh. Pennsylvania: Clinical Trial to 
Assess the Safety. Feasibility, and Efficacy of Transferring a Potentially Anti-arthritic Cytokine Gene to 
Human Joints with Rheumatoid Arthritis. 
RAC Approval: 6-9-94/NIH Approval: Pending 
(M/PB/TIL) 
Freedman, Ralph; MD Anderson Cancer Center, Houston, Texas; Use of a Retroviral Vector to Study 
the Trafficking Patterns of Purified Ovarian TIL Populations Used in Intraperitoneal Adoptive 
Immunotherapy of Ovarian Cancer Patients: A Pilot Study. 
RAC Approval: 6-9-94/NIH Approval: 7-12-94 
((M/PBSC) 
Heslop, Helen; Brenner, Malcolm, K.; and Krance, Robert; St. Jude Childrens Research Hospital, 
Memphis, Tennessee; Use of Double Marking with Retroviral Vectors to Determine the Rate of 
Reconstitution of Untreated and Cytokine Expanded CD34( + ) Selected Marrow Cells in Patients 
Undergoing Autologous Bone Marrow Transplantation. 
RAC Approval: 6-9-94/NIH Approval: 7-12-94 
(T/C/Breast) 
Deisseroth, Albert; Hortobagyi, .Gabriel; Champlin, Richard; and Holmes, Frankie; MD Anderson 
Cancer Center, Houston, Texas;' Use of Safety-Modified Retroviruses to Introduce Chemotherapy 
Resistance Sequences into Normal Hematopoietic Cells for Chemoprotection During the Therapy of 
Breast Cancer A Pilot Trial. 
RAC Approval: 6-9-94/NIH Approval: 7-12-94 
(T/IGD/Fanconi Anemia) 
Liu, Johnson, M. and Young, Neal S.; National Institutes of Health, Bethesda, Maryland; Retroviral 
Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic 
Progenitors of Group C Patients. 
RAC Approval: 6-9-94/NIH Approval: 2-12-94 
(T/C/Non-smal Cell Lung Cancer) 
Roth. Jack A.: MD Anderson Cancer Center. Houston. Texas: Clinical Protocol for Modification of 
Tumor Suppressor Gene Expression and Induction of Apoptosis in Non-Small Cell Lung Cancer 
(NSCLC) with an Adenovims Vector Expressing Wildtvve p53 and Cisplatin. 
RAC Approval: 6-10-94/NIH Approval: Pending 
(T/V/C/Glioblastoma) 
Sobol, Robert and Royston, Ivor; San Diego Regional Cancer Center; San Diego, California; 
Injection of Glioblastoma Patients with Tumor Cells Genetically Modified to Secrete Interleukin-2 (IL- 
2): A Phase I Study. 
RAC Approval: 6-10-94/NIH Approval: 7-12-94 
(T/V/C/Melanoma/T Ceil Lymphoma/Breast/Head and Neck) 
Lotze. Michael T: University of Pittsburgh, Pittsburgh. Pennsylvania: IL-12 Gene Therapy Usine 
Direct Injection of Tumor with Genetically Engineered Autologous Fibroblasts. 
RAC Approval: 6-10-94/NIH Approval: Pending 
(T/V/ C/Prostate) 
Simons, Jonathan; Johns Hopkins Oncology Center, Baltimore, Maryland; Phase I/II Study of 
Autologous Human GM-CSF Gene Transduced Prostate Cancer Vaccines in Patients with Metastatic 
Prostate Carcinoma. 
NIH/ORDA Approval: 8-3-94 (Accelerated Review) 
Recombinant DNA Research, Volume 20 
[499] 
